The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2020 | PRINCEPS study: atezolizumab for resectable NSCLC
Benjamin Besse, MD, PhD, Institut Gustave Roussy, Villejuif, France, discusses results from the PRINCEPS study (NCT02994576), a Phase II clinical trial studying neoadjuvant atezolizumab for resectable non-small cell lung cancer (NSCLC). Results showed that surgery after one infusion of atezolizumab was safe and that the short delay between atezolizumab and surgery might explain the absence of major pathological response. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).
